The 36-month beta value for BBIO is at 1.06. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BBIO is 140.78M, and currently, shorts hold a 14.95% of that float. The average trading volume for BBIO on July 26, 2024 was 1.93M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BBIO) stock’s latest price update
The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) has jumped by 1.29 compared to previous close of 26.36. Despite this, the company has seen a gain of 2.97% in its stock price over the last five trading days. prnewswire.com reported 2024-07-24 that NEW YORK, July 24, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
BBIO’s Market Performance
BridgeBio Pharma Inc (BBIO) has seen a 2.97% rise in stock performance for the week, with a 14.20% gain in the past month and a 6.67% surge in the past quarter. The volatility ratio for the week is 4.48%, and the volatility levels for the past 30 days are at 5.16% for BBIO. The simple moving average for the past 20 days is 1.70% for BBIO’s stock, with a -11.60% simple moving average for the past 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Raymond James repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Raymond James is $45 based on the research report published on March 21, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $37. The rating they have provided for BBIO stocks is “Market Perform” according to the report published on January 31st, 2024.
Wells Fargo gave a rating of “Overweight” to BBIO, setting the target price at $58 in the report published on December 08th of the previous year.
BBIO Trading at -2.16% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.76% of loss for the given period.
Volatility was left at 5.16%, however, over the last 30 days, the volatility rate increased by 4.48%, as shares surge +13.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.32% lower at present.
During the last 5 trading sessions, BBIO rose by +2.97%, which changed the moving average for the period of 200-days by +5.70% in comparison to the 20-day moving average, which settled at $26.41. In addition, BridgeBio Pharma Inc saw -33.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Scott Randal W., who sale 1,500 shares at the price of $31.30 back on Jun 04 ’24. After this action, Scott Randal W. now owns 4,000 shares of BridgeBio Pharma Inc, valued at $46,950 using the latest closing price.
Scott Randal W., the Director of BridgeBio Pharma Inc, sale 1,000 shares at $28.84 during a trade that took place back on Jun 03 ’24, which means that Scott Randal W. is holding 5,500 shares at $28,843 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.18 for the present operating margin
- 0.98 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.46. The total capital return value is set at -0.67.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 2.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at -1.64. The interest coverage ratio of the stock is -10.84.
Currently, EBITDA for the company is -574.64 million with net debt to EBITDA at -2.75. When we switch over and look at the enterprise to sales, we see a ratio of 28.59. The receivables turnover for the company is 0.93for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.54.
Conclusion
In conclusion, BridgeBio Pharma Inc (BBIO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
